Drug Trial Radar · NCT06716021
ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
750
Planned (sponsor's estimate)
Start
Aug 20, 2026
Primary completion
Dec 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- Milestone Pharmaceuticals Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-national, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of etripamil NS in patients with atrial fibrillation (AF). This study includes Screening Visit, Randomization Visit, a Treatment Period with scheduled Follow-up Visits (Monthly Follow-up and Post-treatment Follow-up Visits), a Final Study Visit, and an End of Study Telephone Follow up Visit. Each patient will be randomized 1:1 to receive placebo or 70 mg Etripamil NS regimens. Patients will self-administer study drug for a perceived episode of AF with RVR with an initial dose of placebo or 70 mg etripamil NS, followed by an optional second dose of the same study drug 10 minutes after the first dose if the patient continues to experience symptoms. Patients may treat up to a maximum of 4 episodes in the study. Informed consent will be obtained prior to any study procedures.
Conditions
- Atrial Fibrillation
Interventions
PlaceboDrug
The formulation of placebo will consist of water, sodium acetate, disodium EDTA, and sulfuric acid to reproduce the same pH as the etripamil formulation.
EtripamilDrug
The formulation of etripamil is for IN administration and will consist of etripamil, water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg with an optional second dose of 70 mg 10 minutes after the first dose if symptoms persist.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Demonstrate the efficacy of etripamil NS over placebo in patients with AF.Time frame: 30 minutes from first drug administration
Locations
23 sites in 3 countries. Site status is shown where the registry gives one.
Blue Coast Research Center, LLC
Vista, California · Recruiting
Interventional Cardiology Medical Group (West Hills, CA)
West Hills, California · Recruiting
South Denver Cardiology Associates P.C
Littleton, Colorado · Recruiting
St Luke's Regional Medical Center, Ltd
Boise, Idaho · Recruiting
TidalHealth Peninsula Regional, Inc
Salisbury, Maryland · Recruiting
Cardiovascular Associates Of The Delaware Valley
Haddon Heights, New Jersey · Recruiting
Weill Cornell Medicine
Manhattan, New York · Recruiting
Cardiology Consultants of Philadelphia (CCP)
Yardley, Pennsylvania · Recruiting
The Jackson Clinic, PA
Jackson, Tennessee · Recruiting
Montreal Heart Institute
Montreal, Quebec, Canada · Recruiting
CardioVasc HR Inc
Saint-Jean-sur-Richelieu, Quebec, Canada · Recruiting
Gelre Ziekenhuizen
Apeldoorn, Gelderland, Netherlands · Recruiting
Rijnstate Ziekenhuis
Arnhem, Gelderland, Netherlands · Recruiting
Gelderse Vallei Ziekenhuis
Ede, Gelderland, Netherlands · Recruiting
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, North Brabant, Netherlands · Recruiting
Amphia Ziekenhuis
Breda, North Brabant, Netherlands · Recruiting
Elkerliek Ziekenhuis
Helmond, North Brabant, Netherlands · Recruiting
Bravis ziekenhuis
Roosendaal, North Brabant, Netherlands · Recruiting
Noordwest Ziekenhuisgroep
Alkmaar, North Holland, Netherlands · Recruiting
ZGT
Hengelo, Overijssel, Netherlands · Recruiting
Frisius Medisch Centrum
Leeuwarden, Provincie Friesland, Netherlands · Recruiting
Van Weel-Bethesda Ziekenhuis
Dirksland, South Holland, Netherlands · Recruiting
Ikazia Ziekenhuis
Rotterdam, South Holland, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.